Argenx
ARGX
#408
Rank
S$73.91 B
Marketcap
S$1,187
Share price
-0.63%
Change (1 day)
41.34%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2025 (TTM): S$11.52

According to Argenx 's latest financial reports the company's current EPS (TTM) is S$11.49. In 2024 the company made an earnings per share (EPS) of S$18.04 an increase over its 2023 EPS that were of S-$6.69.

EPS history for Argenx from 2011 to 2025

Annual EPS

Year EPS Change
2025 (TTM)S$11.52-36.11%
2024S$18.04-369.77%
2023S-$6.69-60.46%
2022S-$16.9163.33%
2021S-$10.35-40.37%
2020S-$17.36183.47%
2019S-$6.13123.09%
2018S-$2.7554.93%
2017S-$1.7714.07%
2016S-$1.5513.05%
2015S-$1.37-36.34%
2014S-$2.16209.04%
2013S-$0.70-33.99%
2012S-$1.06185.59%
2011S-$0.37